Bayer (BAYN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic roadmap and financial performance

• Focused on three pillars: replacing top-line revenue post-Xarelto, pipeline renovation, and operating model transformation.

• Upgraded 2023 guidance and confirmed top-end performance, projecting growth for 2024 despite Xarelto's loss of exclusivity.

• Pharmaceuticals and Consumer Health segments achieved sales growth of 4% and 3% respectively, offsetting a 2% decline in Crop Science; EBITDA margin for Pharma reached 26.9% for 9M 2024.

• Margin compression continues due to Xarelto erosion, but cost measures are in place to stabilize margins in the mid-20s.

• Base business remains resilient, especially in radiology and women's health, with over €10 billion expected to remain stable.

Product launches and pipeline highlights

• Nubeqa achieved blockbuster status, surpassing €1 billion in sales, with over 100,000 patients treated and expansion into new prostate cancer indications by 2028.

• Kerendia reached €500 million, building a strong cardiorenal brand with heart failure indication applications submitted in the US and China.

• Acoramidis, for ATTR cardiomyopathy, is launch-ready in Europe and the U.S., targeting a billion-plus market, with launch expected in 2025.

• Elinzanetant, a differentiated non-hormonal therapy for menopausal symptoms, showed strong efficacy and safety in four phase III trials and is expected to launch in 2025.

• Eylea 8mg launched with strong uptake and pre-filled syringe availability, maintaining leadership in the retinal market and compensating for biosimilar competition.

R&D and innovation strategy

• Eight out of nine recent phase III readouts were positive, demonstrating pipeline strength.

• Rapid pipeline replenishment with over 20 clinical programs advanced or completed in 18 months, emphasizing innovative first-in-class and best-in-class assets.

• Investments in chemoproteomics, cell and gene therapy platforms have expanded the global footprint.

• RMAT designation for iPSC cell therapy in Parkinson’s, with phase III trials planned and gene therapy program underway; Phase III trial for bemdaneprocel announced after positive Phase I data.

• Oncology pipeline includes promising TKIs and radioligand therapies, with robust supply chains and early-stage assets.